1. Transformation from operative capability to innovative capability
in Bio-based Agro & Food industries
คณะทรัพยากรชีวภาพและเทคโนโลยี
มหาวิทยาลัยเทคโนโลยีพระจอมเกล้าธนบุรี
December

2. Pharmaceutical and Vaccine Markets
Source: BioExecutive, 2007 modified

3. Development Time and Costs
Source: Intercell, 2008

4. Key Success Factors Plants Projects People Product
Research and Development
Projects
Access to or discovery of cutting edge technologies
Project management and technological risk assessment
Human Resources Development
People
In-house capacity building, “5 years threshold”
Nationwide capacity building, vaccine networking, controlling authorities
Manufacturing capacity
Plants
Investment for downstream and upstream facilities
Project feasibility
Business and Market Development
Product
Thailand (Self-sufficiency) and Export Network (Sustainability)
Return on Investment, break even

5. From Constellation to Consolidation
FIVE STARS
MARKET
Merck
Sanofi
GSK
Pfizer
Baxter
Crucell
CSL
SSI
SBL
Emerging S
Biotech C
Novartis
Baxter
GSK
Aventis Pasteur
Merck
Vaccines
Wyeth
Chiron
CONSOLIDATION
PHASE
Berna
Merck
SSW
P. Vaccins
I. Merieux
IDB
Wyeth
Human
Lederle
Acambis
RIT
Corixa
Rhein B.
CSL
SSI
SBL
Powderject
Behring
Sclavo
NAVA
Sevac
GCVC
Immuno
Duphar
Berna
Crucell
Emerging S
Biotech C

6. Emergence of New Players New Wave of Consolidation
New Scenario in 2009
Consolidation
Sanofi
Intercell
India
China
Emergence of New Players
Merck
SSW
P. Vaccins
I. Merieux
IDB
Wyeth
Human
Lederle
Acambis
RIT
Corixa
Rhein B.
CSL
SSI
SBL
Powderject
Behring
Sclavo
NAVA
Sevac
GCVC
Immuno
Duphar
Berna
Crucell
Emerging S
Biotech C
Merck
New Wave of Consolidation
GSK
Novartis
J&J
Crucell
Baxter

7. Current Vaccine Production/Filling Capacity in ASEAN10
Filling
Production
Vaccines F
Rabies, DTwP, HB, Mea, JE, Flu
HB, Flu HB - P
BCG, JE
DTwP, OPV, Mea, Hib, BCG
DTwP, OPV, BCG, Mea, JE, Flu
Pneu (10-valent)

8. Bringing in International Vaccine Expertise
Experienced Vaccine Management Team
Vitoon Vonghangool
President
42 years
Pasteur Mérieux (Thailand)
Chiron consultant
Pham Hong Thai
CEO.
20 years
Biocine (France)
Chiron (Italy)
Jean Petre
Scientific Dir.
28+7 years
SKB (Belgium)
Chiron(Italy)
PATH consultant
Nadir Harjee
Technical Dir.
37 years
PM Connaught (Canada)
WHO consultant
Veerachai Tarnmaneewongse
Marketing Director
22 years
Sanofi Pasteur (Thailand)
Dario Cresci
Site Director
15+12 years
AstraZeneca
Novartis (Italy)
Rochapon Wacharotayankun
Head, Quality Ops
10 years
GPO-MBP (Thailand)
Athapume Thamrongyuth
Validation Manager
11+29 years
Hoechst, GPO-MBP (Thailand)
Indrajeet Poredi
Research Manager
15 years
Serum Institute Panacea Biotec Shantha, Biotechnics (India)
Mukesh Chauhan
Development Manager
11 years
Panacea Biotec Shantha Biotechnics (India)

9. Bacterial Combination
Broad Product Pipeline
In-house and Licensed Technology Platforms
Acellular pertussis 1
Hepatitis B
Human papilloma
Recombinant protein
Tetanus
TdaP
DTaP-HB
Bacterial Combination
Diphtheria
DTaP-HB-Hib Y
Protein carrier 1
Hib meningitis
Protein conjugation
Chikungunya
HIV?
Dengue
Japanese Encephalitis
Cell culture
Viral 1
HIV ?
2011
2012
2013

10. BioNet-Asia Employees by Education Level
Total 114 13 31 9 38 9 14

11. Vaccine Collaboration National Agenda for Vaccine
Building up Vaccine Capability in Thailand
Fast-track Process
2012
PhD
In-house Training
Vaccine Collaboration
People – Expertise/Skill
National Agenda for Vaccine
Project – Technology
Plant – Facility

12. Vaccine Plant
Pilot Plant from 2006 to 2011

13. Vaccine Plant Three Dedicated Buildings for Production, QC, R&D
Quality Control

14. P15 activities progress

15. Vaccine Plant Medium to Large Scale Bulk Manufacturing Capacities
Bulk Antigen Manufacturing Capacity
(Total doses per year)
Acellular Pertussis
Hepatitis B
Haemophilus Influenzae type b
Diphtheria
Several million doses*
* Depending on antigen produced and assuming production of one antigen per year

16. Vaccine Plant - Site Master Plan
The Largest Vaccine Facility in Thailand (in )

17. Benefits of Building Vaccine Capacity to Thailand
Knowledge and innovation – Key driving factors for sustainable and economic growth in the 21st century
Vaccine self-sufficiency
- Improved quality of life
- National Security
Economic stimulus package
- Rapid growth of GDP
Employment
- Increased job opportunity; professional and skilled workers
- Income distribution
Knowledge pool
Sustaining knowledge creation
Strengthening scientific community
Attracting talents
Increased R&D funds for translational research (High R&D fund/GDP)
Return of value to research “Long term income” for creation of a strong stream of profits
Emergence of local vaccine-related business/industries
Human resource development
Academics, Researcher, Developer, Manufacturer, Regulator
Competitiveness
Increased research / business opportunity
Attracting foreign or multinational companies for business collaboration 17